NCT05503082View on ClinicalTrials.gov

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

November 30, 2024

Conditions
Headache, Migraine
Interventions
DRUG

Ubrogepant 50 MG [Ubrelvy]

Ubrogepant 50 MG \[Ubrelvy\]

DRUG

Ubrogepant 100 MG [Ubrelvy]

Ubrogepant 100 MG \[Ubrelvy\]

Trial Locations (2)

60563

Chicago Headache Center & Research Institute, Naperville

60657

Chicago Headache Center & Research Institute, Chicago

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Chicago Headache Center & Research Institute

OTHER